Perspective Therapeutics partners with Merck to test [212Pb]PSV359 with Keytruda in FAP-α-positive solid tumors
Reuters2026/09/14 10:16- Perspective Therapeutics entered a clinical trial collaboration and supply agreement with Merck to test [212Pb]PSV359 with Keytruda (pembrolizumab).
- Combination will be evaluated via an amendment to Perspective’s ongoing Phase 1/2a study in FAP-α-positive non-small cell lung cancer and colorectal cancer.
- Merck will supply pembrolizumab at no cost; Perspective will sponsor the trial.
- Study has completed enrollment in the first three monotherapy dose cohorts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic partners with Trump-linked company RUM Group (RUM.US)! $13.7 billion computing power deal sparks concerns over conflicts of interest
Anthropic has signed a six-year computing power contract worth a total of 13.7 billions USD with RUM Group. The latter's close ties to Trump have also raised concerns about potential conflicts of interest.
Aberdeen says Japan retail equity holdings top UK despite later investor push
Texas Capital Bancshares Moves Stock Listing to Texas Stock Exchange
NextEra Energy Reaffirms Full-Year Adjusted Earnings Outlook
Crypto prices
More
